Company IXICO PLC London S.E.
Equities
GB00BCLY7L40
Biotechnology & Medical Research
Business Summary
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Clinical Trials Services
100.0
%
| 9 | 100.0 % | 7 | 100.0 % | -22.89% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
45.8
%
| 3 | 31.4 % | 3 | 45.8 % | +12.62% |
United Kingdom
14.3
%
| 2 | 23.8 % | 1 | 14.3 % | -53.72% |
Netherlands
12.9
%
| 0 | 5.0 % | 1 | 12.9 % | +97.71% |
Switzerland
12.2
%
| 2 | 24.0 % | 1 | 12.2 % | -60.71% |
Ireland
10.3
%
| 1 | 8.4 % | 1 | 10.3 % | -4.83% |
Europe
4.4
%
| 1 | 7.4 % | 0 | 4.4 % | -54.08% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Giulio Cerroni
CEO | Chief Executive Officer | 63 | 06/17/06 |
Director of Finance/CFO | 47 | 31/19/31 | |
Charles Spicer
CHM | Chairman | 59 | 14/13/14 |
Romina Oxborough
COO | Chief Operating Officer | - | - |
Robin Wolz
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Michelle Lax
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/12/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Spicer
CHM | Chairman | 59 | 14/13/14 |
Director/Board Member | 49 | 16/16/16 | |
Dipti Amin
BRD | Director/Board Member | 60 | 05/23/05 |
Giulio Cerroni
CEO | Chief Executive Officer | 63 | 06/17/06 |
Director of Finance/CFO | 47 | 31/19/31 | |
Director/Board Member | 57 | 21/22/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 48,351,373 | 24,741,986 ( 51.17 %) | 0 | 51.17 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |